Influence of Cerebral Oedema in Intracerebral Haemorrhage
Launched by UNIVERSITY HOSPITAL, LILLE · Nov 5, 2020
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
The COPITCH study is investigating a type of stroke known as Intracerebral Hemorrhage (ICH), which occurs when there is bleeding inside the brain. This research aims to understand the role of swelling around the bleeding area, called perihaematomal oedema (PHO), and how it affects recovery and treatment options. Currently, there are no specific proven treatments for this condition, so the study hopes to find new ways to help patients who experience ICH.
To participate in this study, individuals should be between the ages of 65 and 74 and have had a spontaneous (non-traumatic) ICH within the last 12 hours. Participants must also be insured under the French social security system and provide consent to join the study. Those with certain conditions, such as previous brain injuries or serious health issues that limit life expectancy, will not be eligible. If you join the study, you can expect to undergo assessments and possibly MRI scans to help researchers learn more about the effects of PHO on recovery from stroke. This research could lead to better treatments for future patients experiencing similar health challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • With a spontaneous ICH, i.e. non traumatic
- • Admitted within 12 hours of stroke onset. For wake-up strokes, time of last seen well will be considered as stroke onset
- • Patient insured under the French social security
- • Consent form signed
- Exclusion Criteria:
- • Pure intraventricular haemorrhages
- • "secondary" ICH: ICH resulting from intracranial vascular malformation, intracranial venous thrombosis, head trauma or tumour; haemorrhagic transformation within an infarct
- • Pre-admission modified Rankin score of 4 or 5
- • Life expectancy of less than 1 year related to comorbidities (end stage cancer, end stage organ failure)
- • Pregnancy or breastfeeding or Women of childbearing age without effective contraception (a pregnancy test will be done)
- • Adults who are deprived of their liberty by judicial or administrative decision
- • Referral from other hospitals
- • Contra-indication to MRI : claustrophobia, ocular metallic foreign bodies (accidental or other) or in a risk area (nervous or vascular system);irremovable implanted medical device (pacemaker, neurostimulator, cochlear implants and others);metallic heart valve (mainly old heart valves) or vascular clips previously implanted on cranial aneurysms; gadolinium allergy
- • No consent form
About University Hospital, Lille
University Hospital Lille is a leading academic medical institution dedicated to advancing healthcare through innovative clinical research and patient-centered care. As a prominent sponsor of clinical trials, the hospital leverages its extensive resources, multidisciplinary expertise, and state-of-the-art facilities to facilitate groundbreaking studies across various medical fields. Committed to enhancing therapeutic options and improving patient outcomes, University Hospital Lille collaborates with researchers, healthcare professionals, and industry partners to ensure rigorous scientific standards and ethical practices in all clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lille, , France
Patients applied
Trial Officials
Charlotte Cordonnier, MD,PhD
Principal Investigator
University Hospital, Lille
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials